ReviewFrontiers in medicine2026
Fatty acid-binding protein 2 in inflammatory bowel disease: mechanistic insights and translational perspectives.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty acid-binding protein 2 (FABP2) is an intestine-specific cytoplasmic lipid chaperone with a molecular weight of approximately 14-15 kDa that plays a pivotal role in the uptake, intracellular trafficking, and metabolism of long-chain fatty acids. Emerging evidence indicates that FABP2 is not only a sensitive biomarker of intestinal mucosal injury but also may contribute to the pathogenesis and progression of IBD, potentially through the modulation of PPARγ signaling pathway, although the underlying mechanisms require further investigation. This review systematically summarizes the structural and functional characteristics of the fatty acid-binding protein (FABP) family members, with particular emphasis on the biological features of FABP2. We discuss the involvement of FABP2 in multisystem diseases and highlight its specific relevance in IBD. Furthermore, we summarize current evidence regarding the potential molecular mechanisms by which FABP2 may influence IBD, including its possible roles in intestinal barrier dysfunction, lipid metabolism, gut microbiota-host interactions, and its potential contribution to the attenuation of intestinal inflammation, possibly through regulation proliferation and differentiation of intestinal stem cells. Although the biological investigations of FABP2 in inflammatory bowel disease (IBD) have yielded promising findings, its clinical translation is still confronted with challenges such as the precise assessment of disease activity and the development of safe and effective targeted therapeutics. Collectively, this review provides a comprehensive reference for researchers and clinicians in the IBD field, highlighting the well-supported role of FABP2 as a diagnostic biomarker while discussing its potential as a therapeutic target, an area that warrants further mechanistic and clinical investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.